Development of hedgehog pathway inhibitors (HPI) in treatment of cancer

Current Chemical Biology

Volumn 8, Issue 3, 2015, Pages 132-148

  Pramanik, Dipankar ^a  

^a HALDIA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Cancer; Gli1; Hedgehog; Patched; Smoothened; ViSmodegib

Indexed keywords

ARSENIC TRIOXIDE; BMS 833923; CYCLOPAMINE; GANT 58; GANT 61; GLASDEGIB; HEDGEHOG PATHWAY INHIBITOR; HEDGEHOG PATHWAY INHIBITOR 1; HEDGEHOG PATHWAY INHIBITOR 2; HEDGEHOG PATHWAY INHIBITOR 3; HEDGEHOG PATHWAY INHIBITOR 4; ITRACONAZOLE; LEQ 506; PATIDEGIB; PF 5274857; PROTEIN ANTIBODY; PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN; SONIC HEDGEHOG PROTEIN ANTIBODY; SONIDEGIB; TALADEGIB; UNCLASSIFIED DRUG; VISMODEGIB;

ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG INHIBITION; DRUG RESISTANCE; DRUG SCREENING; HUMAN; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ERINACEIDAE;

EID: 84929326817     PISSN: 22127968     EISSN: 18723136     Source Type: Journal    
DOI: 10.2174/221279680803150420094427     Document Type: Article

References (138)

1. Strizzi L, Hardy KM, Seftor EA, et al. Development and cancer: at the crossroads of Nodal and Notch signaling. Can Res 2009; 699180: 7131-34.
2. Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 1980; 287: 795-801.
3. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001; 15(23): 3059-87.
4. McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 2003; 53: 1-114.
5. McMillan R, Matsui W. Molecular Pathways: The Hedgehog Signaling Pathway in Cancer. Clin Can Res 2012; 18(18): 4882-8.
6. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008; 22(18): 2454-72.
7. Eggenschwiler JT, Anderson KV. Cilia and developmental signaling. Annu Rev Cell Dev Biol 2007; 23: 345-73.
8. Wong SY, Reiter JF. The primary cilium at the crossroads of mammalian hedgehog signaling. Curr Top Dev Biol 2008; 85: 225-60.
9. Sasaki H, Nishizaki Y, Hui C, Nakafuku M, Kondoh H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development 1999; 126(17): 3915-24.
10. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85(6): 841-51.
11. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995; 13(1): 113-25.
12. Sun LS, Li XF, Li TJ. PTCH1 and SMO gene alterations in keratocystic odontogenic tumors. J Dent Res 2008; 87(6): 575-9.
13. Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996; 14(1): 78-81.
14. Epstein, E.H. Basal cell carcinomas: attack of the hedgehog. Nat Rev Can 2008; 8(10): 743-54.
15. Raffel C, Jenkins RB, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutations. Can Res 1997; 57(5): 842-45.
16. Vorechovsky I, Tingby O, Hartman M, et al. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 1997; 15(3): 361-66.
17. Barreto DC, Gomez RS, Bale AE, Boson WL, De Marco L. PTCH gene mutations in odontogenic keratocysts. J Dent Res 2000; 79(6): 1418-22.
18. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391(6662): 90-92.
19. Lam CW, Xie J, To KF, et al. A frequent activated Smoothened mutation in sporadic basal cell carcinomas. Oncogene 1999; 18(3): 833-36.
20. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Can Res 1998; 58(9): 1798-803.
21. Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339(6123): 1077-80.
22. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002; 31(3): 306-10.
23. Brugieres L, Remenieras A, Pierron G, et al. High frequency of germline SUFU mutations in children with deSmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol 2012; 30(17): 2087-93.
24. Mao J, Ligon KL, Rakhlin EY, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Can Res 2006; 66(20): 10171-78.
25. Corcoran RB, Scott MP. A mouse model for medulloblastoma and basal cell nevus syndrome. J Neurooncol 2001; 53(3): 307-18.
26. Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 1998; 4(5): 619-22.
27. Wetmore C, Eberhart DE, Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Can Res 2000; 60(8), 2239-46.
28. Kimura H, Stephen D, Joyner A, Curran T. Gli1 is important for medulloblastoma formation in Ptc1+/− mice. Oncogene 2005; 24(25): 4026-36.
29. Nilsson M, Undèn AB, Krause D, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci USA 2000; 97(7): 3438-43.
30. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small- cell lung cancer. Nature 2003; 422(6929): 313-17.
31. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine- mediated hedgehog pathway inhibition depletes stemlike cancer cells in glioblastoma. Stem Cells 2007; 25(10): 2524-33.
32. Dierks C, Grbic J, Zirlik K, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007; 13(8): 944-51.
33. Yauch RL, Gould SE, Scales SJ, et al. Aparacrine requirement for hedgehog signalling in cancer. Nature 2008; 455(7211): 406-10.
34. Gallinari P, Filocamo G, Jones P, Pazzaglia S, Steinkühler C. Smoothened antagonists: a promising new class of antitumor agents. Exp Opin Drug Disc 2009; 4(5): 525-44.
35. Ericson J, Morton S, Kawakami A, Roelink H, Jessell TM. Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identity. Cell 1996; 87(4): 661-73.
36. Maun HR Wen X, Lingel A, et al. Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site. J Biol Chem 2010; 285(34): 26570-80.
37. Qualtrough D, Buda A, Gaffield W, Williams AC, Paraskeva C. Hedgehog signalling in colorectal tumour cells: induction of apoptosis with cyclopamine treatment. Int J Cancer 2004; 110(6): 831-37.
38. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324(5933): 1457-61.
39. Petrova E, Rios-Esteves J, Ouerfelli O, Glickman JF, Resh MD. Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling. Nat. Chem Biol 2013; 9(4): 247-49.
40. Stanton BZ, Peng LF, Maloof N, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol 2009; 5(3): 154-56.
41. Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen- mediated inhibition of target tissue response to Shh signalling. Science 1998; 280(5369): 1603-07.
42. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002; 16(21): 2743-48.
43. Peukert S, Miller-Moslin K. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. ChemMedChem 2010; 5(4): 500-12.
44. Wetmore C, Eberhart DE, Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Can Res 2000; 60(8): 2239-46.
45. Pazzaglia S, Mancuso M, Atkinson MJ, et al. High incidence of medulloblastoma following X-ray- irradiation of newborn Ptc1heterozygous mice. Oncogene 2002; 21(49): 7580-84.
46. Hatton BA, Villavicencio EH, Tsuchiya KD, et al. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Can Res 2008; 68(6): 1768-76.
47. Grachtchouk M, Mo R, Yu S, et al. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet 2000; 24(3): 216-17.
48. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Can Res 1993; 53(2): 5535-41.
49. Dahlen A, Fletcher CD, Mertens F, et al. Activation of the GLI oncogene through fusion with the beta- actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7; 12). Am J Pathol 2004; 164(5): 1645-53.
50. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Can Res 2007; 67(5): 2187- 96.
51. Lin T, Matsui W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targ Ther 2012: 5; 47-58.
52. Tremblay MR, Lescarbeau A, Grogan MJ, et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009; 52(14): 4400-18.
53. Lee MJ, Hatton BA, Villavicencio EH, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci USA 2012; 109(20): 7859-64.
54. Hwang S, Thangapandian S, Lee KW. Molecular dynamics simulations of sonic hedgehog-receptor and inhibitor complexes and their applications for potential anticancer agent discovery. PLoS One 2013; 8(7): e68271.
55. Jimeno A, Weiss GJ, Miller WH Jr, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Can Res.2013; 19(10): 2766-74.
56. Rudin C, Jimeno A, Miller W. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients with advanced or metastatic solid tumors [abstract]. J Clin Oncol 2011; 29: 3014.
57. Stephenson J, Richards D, Wolpin B. The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients with metastatic pancreatic cancer [abstract]. J Clin Oncol 2011; 29: 4114.
58. Peluso MO, Campbell VT, Harari JA, et al. Impact of the Smoothened inhibitor, IPI-926, on Smoothened ciliary localization and Hedgehog pathway activity. PLoS One 2014; 9(3): e90534.
59. Wagner AHP, Okuno S, Eriksson M, et al. Results from a phase 2 randomized, placebo-controlled, double blind study of the hedgehog (HH) athway antagonist IPI-926 in patients (PTS) with advanced chondrosarcoma (CS). Connective tissue oncology society 18th annual meeting; New York, NY; 2013.
60. Pan S, Wu X, Jiang J, et al. Discovery of NVPLDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett 2010; 1(3): 130-34.
61. Muraglia E, Ontoria JM, Branca D, et al. N-(2- alkylaminoethyl)- 4-(1,2,4-oxadiazol-5-yl)piperazine-1- carboxamides as highly potent Smoothened antagonists. Bioorg Med Chem Lett 2011; 21(18): 5283-88.
62. Tao H, Jin Q, Koo D, et al. Small molecule antagonists in distinct binding modes inhibit drug- resistant mutant of Smoothened. Chem Biol 2011; 18(4): 432-37.
63. Strand MF, Wilson SR, Dembinski JL, et al. A novel synthetic Smoothened antagonist transiently inhibits pancreatic adenocarcinoma xenografts in a mouse model. PLoS One 2011; 6(6): e19904
64. Rodon Ahnert J, Baselga J, Tawbi H, et al. A phase I dose-escalation study of LDE225, a Smoothened (Smo) antagonist, in patients with advanced solid tumors [abstract]. J Clin Oncol 2010; 28: 2500.
65. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a Smoothened inhibitor. J Invest Dermatol 2011; 131(8): 1735-44.
66. Gendreau SB, Hawkins D, Ho C, et al. Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Mol Can Ther 2009; 8: Meeting Abstract Supplement.
67. Siu L, Papadapoulos K, Alberts S. A first-in-human phase 1study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics. November 15-19, 2009; Boston, MA; 2009.
68. Huff CA, Padmanabhan S, Kelly KR, et al. A phase I study of an oral hedgehog pathway antagonist, BMS- 833923, in patients with relapsed or refractory multiple myeloma. Blood 2011; 118: s3993.
69. Munchhof MJ, Li Q, Shavnya A, et al. Discovery of PF-04449913, a potent andorally bioavailable inhibitor of Smoothened. ACS Med Chem Lett 2012; 3(2): 106-11.
70. Wagner AJ, Messersmith WA, Shaik MN, et al. A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors. Clin Can Res. 2014; 1116.2014. [Epub ahead of print]
71. Shaik MN, LaBadie RR, Rudin D, Levin WJ. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the Smoothened inhibitor PF- 04449913 in healthy volunteers. Can Chem Pharm 2014; 74(2): 411-18.
72. Jamieson C, Cortes JE, Oehler V, et al. Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. Blood 2011; 118: s424.
73. Rohner A, Spilker ME, Lam JL, et al. Effective targeting of hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the bloodbrain barrier. Mol Can Ther 2012; 11: 57-65.
74. Miller-Moslin K, Peukert S, Jain RK, et al. 1- amino- 4-benzylphthalazines as orally bioavailable Smoothened antagonists with antitumor activity. J Med Chem 2009; 52(13): 3954-68.
75. Peukert S, He F, Dai M, et al. Discovery of NVPLEQ506, a second-generation inhibitor of Smoothened. ChemMedChem 2013; 8(8): 1261-65.
76. Bender MH, Hipskind PA, Capen AR, et al. Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling. Can Res 2011; 71: abstract 2819
77. Williams JA, Guicherit OM, Zaharian B I, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions.Proc Natl Acad Sci USA 2003; 100(8): 4616-21.
78. Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009; 19(19): 5576-81.
79. Brunton SA, Stibbard JHA, Rubin LL, et al. Potent inhibitors of the hedgehog signaling pathway. J Med Chem 2008; 51(5): 1108-10.
80. Rudin CM, Hann CL, Laterra J, et al. Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. N Engl J Med 2009; 361(12): 1173-78.
81. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of viSmodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366(23): 2171-79.
82. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009; 361(12): 1164-72.
83. Amin SH, Tibes R, Kim JE, Hybarger CP. Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope 2010; 120(12): 2456-9.
84. Lorusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor viSmodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Can Res 2011; 17(17): 2502-11.
85. Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog athway inhibitor viSmodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17(17): 5774-82.
86. Rudin CM. ViSmodegib. Clin Cancer Res 2012; 18(12): 3218-3222.
87. Axelson M, Liu K, Jiang X, et al. U.S. Food and Drug Administration approval: viSmodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Can Res 2013; 19(9): 2289-93.
88. Feldmann G, Habbe N, Dhara S, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model ofpancreatic cancer. Gut 2008; 57(10): 1420-30.
89. Graham RA, Hop CE, Borin MT, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor viSmodegib in healthy female subjects. Br J Clin Pharm 2012; 74(5): 788-96.
90. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012: 366(23): 2180-88.
91. Lauth M, Bergström A, Shimokawa T, Toftgård R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA. 2007; 104(20): 8455-60.
92. Fu J, Rodova M, Roy SK, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Can Lett 2013; 330(1): 22-32.
93. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci USA. 2002; 99(22): 14071-76.
94. Frank-Kamenetsky M, Zhang XM, Bottega S, et al. Small-molecule modulators of Hedgehog signaling: Identification and characterization of Smoothened agonists and antagonists. J Biol 2002; 1(2): 10.
95. Hyman JM, Firestone AJ, Heine VM, et al. Smallmolecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci USA. 2009; 106(33): 14132-37.
96. Chenna V, Hu C, Pramanik D, et al. A polymeric nanoparticle encapsulated small-molecule inhibitor ofhedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Can Ther 2012; 11(1): 165-173.
97. Xu Y, Chenna V, Hu C, et al. Polymeric nanoparticleencapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Can Res 2012; 18(5): 1291-302.
98. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA 2010; 107(30): 13432-37.
99. Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 2011; 121(1): 148-60.
100. Banerjee U, Hadden MK. Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies. Expert Opin Drug Discov 2014; 9(7): 751-71.
101. Kerl K, Moreno N, Holsten T, et al. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. Int J Can 2014; 135(4): 989-95.
102. Nakamura S, Nagano S, Nagao H, et al. Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation. PLoS One. 2013; 8(7): e69466
103. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Can Cell 2010; 17(4): 388-99.
104. Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014; 32(8): 745-51.
105. Rudin CM, Brahmer JR, Juergens RA, et al. Phase 2 Study of Pemetrexed and Itraconazole as Second- Line Therapy for Metastatic Non-Squamous Non- Small Cell Lung Cancer. J Thorac Oncol 2013; 8(5): 619-23.
106. Bassilana F, Carlson A, Da Silva JA, et al. Target identification for a hedgehog pathway inhibitor reveals the receptor GPR39. Nat Chem Biol 2014; 10(5): 343-49.
107. Mahindroo N, Connelly MC, Punchihewa C, et al. Structure-activity relationships and cancer-cell selective toxicity of novel inhibitors of gliomaassociated oncogene homologue 1 (Gli1) mediated transcription. J Med Chem 2009; 52(14): 4277-87.
108. Bosco-Clement G, Zhang F, Chen Z, et al. Targeting gli transcription activation by small molecule suppresses tumor growth. Oncogene 2014; 33(16): 2087- 97.
109. Ericson J, Morton S, Kawakami A, Roelink H, Jessell TM. Two critical periods of sonic hedgehog signaling required for the specification of motor neuron identity. Cell 1996; 87(4): 661-73.
110. Michaud NR, McEachern KA, et al. Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Mol Can Ther 2014; 13(2): 386-398.
111. Ślusarz A, Shenouda NS, Sakla MS, et al. Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer. Can Res 2010; 70(8): 3382-90.
112. Elamin MH, Shinwari Z, Hendrayani S-F, et al. Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol. Carcinogenesis 2010; 49(3): 302-14.
113. Fan P, Fan S, Wang H, et al. Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway. Stem Cell Res Ther 2013; 4(6): 146.
114. Zhang L, Li L, Jiao M, et al. Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway. Can Lett 2012; 323(1): 48-57.
115. Tang JY, Xiao TZ, Oda Y, et al. Vitamin D3 inhibits hedgehog signaling and proliferation in murine basal cell carcinomas. Can Prev Res 2011; 4(5): 744-51.
116. DeBerardinis AM, Banerjee U, Miller M, Lemieux S, Hadden MK. Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway. Bioorg Med Chem Lett 2012; 22(14): 4859- 63.
117. Wang J, Mook Jr. RA, Lu J, et al. Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signalling. Bioorg Med Chem 2012; 20(22): 6751-57.
118. Xin M, Wenb J, Tang F, et al. Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signalling. Bioorg Med Chem Lett 2014; 24(3): 983-88.
119. Xin M, Wen J, Tang F, et al. The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors. Bioorg. Med. Chem. Let. 2013; 23(24): 6777-83.
120. Ontoria JM, Bufi LL, Torrisi C, et al. Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol- 5-yl] piperazinyl ureas as potent Smoothened antagonist hedgehog pathway inhibitors. Bioorg Med Chem Lett 2011; 21(18): 5274-82.
121. Malancona S, Altamura S, Filocamo G, et al. Identification of MK-5710 ((8aS)-8a-methyl-1,3- dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1- phenyl-1Hpyrazol- 5-yl)hexahydroimidazo[1,5-a]pyrazine- 7(1H)-carboxamide), a potent Smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 1. Bioorg Med Chem Lett 2011; 21(15): 4422-28.
122. Kinzel O, Alfieri A, Altamura S, et al. Identification of MK-5710 ((8aS)-8a-methyl-1,3- dioxo-2-[(1S,2R)- 2-phenylcyclo- propyl]-N-(1- phenyl-1H-pyrazol-5-yl) hexahydro-imidazo[1,5- a]pyrazine-7(1H)-carboxamide), a potent Smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2. Bioorg Med Chem Lett 2011; 21(15): 4429-35.
123. Li B, Fei DL, Flaveny CA, et al. Pyrvinium Attenuates Hedgehog Signaling Downstream of Can Res 2014; 74(17): 4811-21.
124. Tao H, Jin Q, Koo D, et al. Small Molecule Antagonists in Distinct Binding Modes Inhibit Drug- Resistant Mutant of Smoothened. Chem Biol 2011; 18(4): 432-37.
125. Nedelcu D, Liu J, Xu Y, Jao C, Salic A. Oxysterol binding to the extracellular domain of Smoothened in hedgehog signaling. Nat Chem Biol 2013; 9(9): 557-64.
126. Wang Y, Arvanites AC, Davidow L, et al. Selective identification of hedgehog pathway antagonists by direct analysis of Smoothened ciliary translocation. ACS Chem Biol 2012; 7(6): 1040-48.
127. Ardecky R, Madiraj C, Matsuzawa S, et al. Selective UBC 13 Inhibitors Probe Reports from the NIH Molecular Libraries Program. (http: //www.ncbi.nlm. nih.gov/books/NBK143542/).
128. Tang Y, Gholamin S, Schubert S, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med 2014; 20(7): 732-42.
129. Pei XH, Ayad NG, Wahlestedt DJ, et al. The BET bromodomain inhibitor I-BET151 acts downstream of Smoothened to abrogate the growth of Hedgehog driven cancers. J Biol Chem 2014: 10.1074/jbc. M114.595348. [Epub ahead of print]
130. Yauch RL, Dijkgraaf GJP, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326(5952): 572-74.
131. Wang C, Wu H, Katritch V, et al. Structure of the human Smoothened receptor bound to an antitumour agent. Nature 2013; 497(7449): 338-43.
132. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory Smoothened mutants and downstream mechanisms of drug resistance. Can Res 2011; 71(2): 435-44.
133. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to Smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010; 2(51): 51ra70.
134. Wang Y, Ding Q, Yen CJ, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012; 21(3): 374-87.
135. Du W, Liu X, Chen L et al. Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness. 2015; 17(2): 243-53.
136. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 2013; 19(11): 1410-22.
137. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008; 455(7211): 406-10.
138. Kim J, Rudin C. Hedgehog Signaling Pathway: Therapeutic Abrogation of a Fundamental Developmental Molecular Pathway. ASCO Annual Meeting, 2014.